• Please log in or register to access this feature.

Intervention Protocol

Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C

  1. Tahany Awad1,*,
  2. Kristian Thorlund2,
  3. Goran Hauser3,
  4. Mahasen Mabrouk4,
  5. Davor Stimac3,
  6. Christian Gluud1

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 8 SEP 2008

DOI: 10.1002/14651858.CD005642.pub2

Database Title

Additional Information

How to Cite

Awad T, Thorlund K, Hauser G, Mabrouk M, Stimac D, Gluud C. Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No.: CD005642. DOI: 10.1002/14651858.CD005642.pub2.

Author Information

  1. 1

    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Cochrane Hepato-Biliary Group, Copenhagen, Denmark

  2. 2

    Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

  3. 3

    Clinical Hospital Centre of Rijeka, Clinics of Internal Medicine - Gastroenterology, Rijeka, Croatia

  4. 4

    Faculty of Medicine, Cairo University, Endemic Medicine, Department 2, Cairo, Egypt

*Tahany Awad, Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 3344, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen, DK-2100, Denmark. tahany@ctu.rh.dk.

Publication History

  1. Publication Status: Amended to reflect a change in scope (see 'What's new')
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Full (180K)
 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the benefits and harms of pegylated interferon alpha 2a versus pegylated interferon alpha 2b for patients with chronic hepatitis C.

View Full Article (HTML) Full (180K)